Product Watch

Article

All the latest product news and developments, December 2008

Please click on any of the headlines below to see the full story.

Antioxidant dry AMD eye drop
An antioxidant eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration (AMD). 

Graft rejection therapy enters Phase III
GS-101, Gene Signal's experimental topical ophthalmic solution designed to prevent the rejection of corneal grafts, has entered Phase III trials. 

Investigating Collamer's accommodation
STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL). 

Novagali withdraws drug marketing application
Novagali Pharma SA has withdrawn the EMEA centralized marketing authorization application for Vekacia (cyclosporin) 0.05% eye drops, which had been intended for the treatment of vernal keratoconjunctivitis (VKC). 

European expansion of retinal implant trial
The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer. 

 

For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.